1440753-74-1 Usage
Chemical Class
N-acyl-alpha amino acids and derivatives
This compound belongs to a class of organic compounds that have an amide group attached to an alpha amino acid.
Derivative of Piperidinecarboxylic Acid
The compound is derived from piperidinecarboxylic acid, which is a cyclic amine with a carboxylic acid group.
1,1-Dimethylethyl Ester Group
The compound has a 1,1-dimethylethyl ester group attached to it, which is an ester formed by the reaction of a carboxylic acid with an alcohol.
4-[2-Hydroxy-1-(2-phenyl-1H-benziMidazol-1-yl)ethyl] Moiety
This part of the compound contains a 2-phenyl-1H-benzimidazole group attached to a hydroxyethyl group, which is connected to the piperidine ring.
Structural Similarity to Benzodiazepines
The compound has a similar structure to benzodiazepines, a class of drugs known for their sedative and anxiolytic effects.
Potential Pharmaceutical Applications
Due to its structural similarity to benzodiazepines, the compound may have potential pharmaceutical applications. However, further research is needed to fully understand its properties and potential uses.
Check Digit Verification of cas no
The CAS Registry Mumber 1440753-74-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,4,0,7,5 and 3 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1440753-74:
(9*1)+(8*4)+(7*4)+(6*0)+(5*7)+(4*5)+(3*3)+(2*7)+(1*4)=151
151 % 10 = 1
So 1440753-74-1 is a valid CAS Registry Number.
1440753-74-1Relevant articles and documents
BENZIMIDAZOLES FOR THE TREATMENT OF CANCER
-
, (2014/03/22)
The present invention relates to novel substituted benzimidazoles and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted benzimidazoles together with pharmaceutically acceptable carrier, excipient and/or diluents. Said novel substituted benzimidazoles binding to the prenyl binding pocket of PDEδ have been identified as useful for the prophylaxis and treatment of cancer by the inhibition of the binding of PDEδ to K-Ras and of oncogenic Ras signalling in cells by altering its localization leading to cell death or inhibition of proliferation.
Benzimidazoles for the treatment of cancer
-
Paragraph 0099-0100, (2014/03/22)
The present invention relates to novel substituted benzimidazoles and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted benzimidazoles together with pharmaceutically acceptable carrier, excipient and/or diluents. Said novel substituted benzimidazoles binding to the prenyl binding pocket of PDEδ have been identified as useful for the prophylaxis and treatment of cancer by the inhibition of the binding of PDEδ to K-Ras and of oncogenic Ras signalling in cells by altering its localization leading to cell death or inhibition of proliferation.